Prothena | Spese Di Vendita E Di Amministrazione



Selling And Administration Expenses Cambiamento Data
Acadia Pharmaceuticals USD 130.08M 3.21M 2024-12
Agios Pharmaceuticals USD 51.7M 13.16M 2024-12
ALKERMES USD 146.99M 3.39M 2024-12
Alnylam Pharmaceuticals USD 295.34M 74.35M 2024-12
Amgen USD 1.88B 253M 2024-12
Biogen USD 677.3M 99.6M 2024-12
BioMarin Pharmaceutical USD 256.77M 46.81M 2024-12
Exelixis USD 134.33M 22.53M 2025-01
Incyte USD 326.71M 17.5M 2024-12
Intra Cellular Therapies USD 137.73M 5.63M 2024-12
Ionis Pharmaceuticals USD 88.08M 26.44M 2024-12
MacroGenics USD 14.1M 319K 2024-09
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Prothena USD 16.85M 88K 2024-12
Regeneron Pharmaceuticals USD 792.2M 77.8M 2024-12
Ultragenyx Pharmaceutical USD 82.49M 2.14M 2024-12
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12



Prothena Spese Di Vendita E Di Amministrazione - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Mar 2025.